The Effect Of Oral Ibandronate In Male Osteoporosis

PHASE3CompletedINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Male Osteoporosis
Interventions
DRUG

Ibandronate

Ibandronate orally (tablet) at a dose of 150 mg once per month

DRUG

placebo

Placebo orally (tablet) at a dose of 150 mg once per month

Trial Locations (41)

16635

GSK Investigational Site, Duncansville

20817

GSK Investigational Site, Bathesda

20902

GSK Investigational Site, Wheaton

23249

GSK Investigational Site, Richmond

24153

GSK Investigational Site, Salem

25801

GSK Investigational Site, Beckley

28801

GSK Investigational Site, Asheville

29407

GSK Investigational Site, Charleston

30033

GSK Investigational Site, Decatur

30342

GSK Investigational Site, Atlanta

30501

GSK Investigational Site, Gainsville

33136

GSK Investigational Site, Miami

33156

GSK Investigational Site, Miami

33409

GSK Investigational Site, West Palm Beach

33761

GSK Investigational Site, Clearwater

34684

GSK Investigational Site, Palm Harbor

40202

GSK Investigational Site, Louisville

46250

GSK Investigational Site, Indianapolis

53705

GSK Investigational Site, Madison

55125

GSK Investigational Site, Woodbury

60611

GSK Investigational Site, Chicago

61615

GSK Investigational Site, Peoria

61822

GSK Investigational Site, Champaign

65807

GSK Investigational Site, Springfield

74104

GSK Investigational Site, Tulsa

75216

GSK Investigational Site, Dallas

80501

GSK Investigational Site, Longmont

85704

GSK Investigational Site, Tucson

87106

GSK Investigational Site, Albuquerque

90211

GSK Investigational Site, Beverly Hills

92260

GSK Investigational Site, Palm Desert

94598

GSK Investigational Site, Walnut Creek

94609

GSK Investigational Site, Oakland

94904

GSK Investigational Site, Greenbrae

97201

GSK Investigational Site, Portland

98108

GSK Investigational Site, Seattle

98144

GSK Investigational Site, Seattle

35294-3708

GSK Investigational Site, Birmingham

66160-7820

GSK Investigational Site, Kansas City

04106

GSK Investigational Site, South Portland

02908

GSK Investigational Site, Providence

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Hoffmann-La Roche

INDUSTRY

NCT00397839 - The Effect Of Oral Ibandronate In Male Osteoporosis | Biotech Hunter | Biotech Hunter